Plain-English translation of NCT06791681 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new treatment called for multiple myeloma that has come back or stopped responding to standard drugs. is a type of cell therapy that uses a modified virus to deliver instructions to your immune cells, teaching them to recognize and attack myeloma cancer cells. The study will evaluate whether this treatment is safe and how well it works, with participants followed for 2 years after receiving it.
Multiple myeloma is a blood cancer that often comes back or becomes resistant to standard treatments, leaving patients with limited options. This medication represents a new approach using the body's own immune system to fight the cancer in ways that previous therapies could not.
You likely qualify if…
You likely don't qualify if…
You would receive the medication as an infusion after being given medications to help prevent side effects. The trial uses a dose-escalation design, meaning the first small groups of participants receive lower doses to ensure safety before doses are increased. You would then be followed with regular visits and tests over 2 years to check for safety, side effects, and how well the treatment is working against your myeloma.
AI-generated summary from trial data · Jul 12, 2026 · Not medical advice
China
Phase
Safety & dosing
Sponsor
Chunrui Li
Collaborators
Shenzhen Pregene Biopharma Co., Ltd.
Enrollment target
~24 participants
Started
January 2025
Primary completion
November 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in February 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Chunrui Li
Chunrui Li
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.